Host Inflammatory Pathways

Host inflammatory pathways encompass the integrated network of molecular signals and cellular processes that mediate an organism's response to harmful stimuli, such as pathogens, damaged cells, or irritants [1, 2]. These pathways are characterized by the activation of pattern recognition receptors, the induction of intracellular signaling hubs like NF-κB and JAK/STAT, and the subsequent release of inflammatory mediators including cytokines, chemokines, and lipid signaling molecules [2, 8, 16]. While these responses are vital for host defense and tissue repair, their dysregulation is a central driver of diverse pathologies, ranging from acute cytokine storms in viral infections to chronic inflammation in autoimmune and metabolic diseases [4, 6, 18]. Therapeutic strategies targeting these pathways, known as host-directed therapies, aim to restore immunological balance by either suppressing excessive inflammation to prevent collateral tissue damage or augmenting specific immune functions to enhance disease resolution [3, 12, 15]. Consequently, drugs such as corticosteroids, cytokine inhibitors, and kinase inhibitors are frequently employed to modulate these pathways across a wide spectrum of clinical indications [4, 9, 13, 17]. Monitoring these pathways often involves measuring systemic biomarkers like C-reactive protein and specific cytokines to assess disease activity and treatment response [5, 7, 10]. However, therapeutic intervention carries risks, primarily related to the potential for over-suppression of the immune system and increased vulnerability to opportunistic infections [3, 11, 17].

Other names

Host immune pathwaysHost-directed inflammatory responsePro-inflammatory signaling cascadesHost-directed therapy targets

Modulation of host immune response through inhibition of pro-inflammatory signaling cascades, cytokine neutralization, or activation of anti-inflammatory pathways [3, 8, 17].